Icon

CABENUVA KIT (nda212888)- (400MG/2ML (200MG/ML);600MG/2ML (300MG/ML),600MG/3ML (200MG/ML);900MG/3ML (300MG/ML))

CABOTEGRAVIR; RILPIVIRINE VIIV HLTHCARE
400MG/2ML (200MG/ML);600MG/2ML (300MG/ML),600MG/3ML (200MG/ML);900MG/3ML (300MG/ML)
No No
2031-Sep-15 2026-Jan-21
None None
None No
CABENUVA, a 2-drug co-packaged product of cabotegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
0 0 0
Total Other Developers 1
Drugs with Suitability No
400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) ** ** - - -
600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.